Quick Answer
Evofem Biosciences, Inc. reported Research And Development Expense of $1.85 million for the year ending 2024.
- Evofem Biosciences, Inc. showed a decrease of -37.2% in Research And Development Expense from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $1.38 million | Q2 2014: $932.1 thousand | Q3 2014: $942.7 thousand | Q1 2015: $4.70 million | Q2 2015: $7.47 million | Q3 2015: $15.21 million | Q1 2016: $3.26 million | Q2 2016: $1.43 million | Q3 2016: $964.9 thousand | Q1 2017: $1.98 million | Q2 2017: $4.08 million | Q3 2017: $6.26 million | Q1 2018: $11.96 million | Q2 2018: $11.83 million | Q3 2018: $9.85 million | Q1 2019: $7.89 million | Q2 2019: $5.25 million | Q3 2019: $5.66 million | Q1 2020: $4.25 million | Q2 2020: $2.64 million | Q3 2020: $4.22 million | Q1 2021: $7.26 million | Q2 2021: $8.51 million | Q3 2021: $8.70 million | Q1 2022: $10.39 million | Q2 2022: $7.74 million | Q3 2022: $5.21 million | Q1 2023: $540.0 thousand | Q2 2023: $402.0 thousand | Q3 2023: $614.0 thousand | Q1 2024: $594.0 thousand | Q2 2024: $270.0 thousand | Q3 2024: $332.0 thousand.
- Over the full 12 years of available data (2013 to 2024), Evofem Biosciences, Inc.'s Research And Development Expense has declined by 83.9%.
- Historical annual values: Fiscal year 2024: $1.85 million | Fiscal year 2023: $2.94 million | Fiscal year 2022: $25.03 million | Fiscal year 2021: $33.13 million | Fiscal year 2020: $17.05 million | Fiscal year 2019: $22.23 million | Fiscal year 2018: $43.42 million | Fiscal year 2017: $23.54 million | Fiscal year 2016: $6.58 million | Fiscal year 2015: $34.41 million | Fiscal year 2014: $5.17 million | Fiscal year 2013: $11.45 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: